skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: The MIT/NEMC program in neutron capture therapy

Conference · · Transactions of the American Nuclear Society; (United States)
OSTI ID:6953599
 [1]
  1. Massachusetts Inst. of Tech., Cambridge (United States)

In recent years, research in neutron capture therapy (NCT) for treatment of cancer has accelerated in several centers around the world. At the Massachusetts Institute of Technology (MIT), where much of the initial work in NCT was carried out and where there is a >30-yr history of NCT research, there is currently an active effort designed to reach the clinical trial phase in 1992. The current program is based on an interdisciplinary and interinstitutional collaboration between the Tufts New England Medical Center (NEMC) and MIT's Nuclear Reactor Laboratory. The NEMC/MIT program focuses the capabilities of nuclear engineers, nuclear engineers, nuclear physicists, medical physicists, radiation oncologists, neurosurgeons, neuropathologists, radiobiologists, and dermatologists on the many technical and scientific tasks that must be resolved before human trials are possible. Neutron capture therapy is a bimodal therapy requiring the delivery of the neutron capture agent to the cancer cells, where it must concentrate to significantly higher levels than in healthy tissue, and the delivery of neutron irradiation to the tumor with suitable neutron beams. Currently, NCT with {sup 10}B as the capture agent (BNCT) offers the most promise. The results reported here are based on the {sup 10}B delivery agent boronophenylalanine (BPA). This paper reviews some aspects of this project.

OSTI ID:
6953599
Report Number(s):
CONF-920606-; CODEN: TANSA
Journal Information:
Transactions of the American Nuclear Society; (United States), Vol. 65; Conference: American Nuclear Society annual meeting, Boston, MA (United States), 7-12 Jun 1992; ISSN 0003-018X
Country of Publication:
United States
Language:
English